Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | DRD4 | P21917 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7036046 | 1.00 | ITGB3 (0.57) | ITGB3ITGA2BFFAR4FFAR1DRD2 | |
| SCHEMBL6350179 | 1.00 | ITGB3 (0.57) | ITGB3ITGA2BFFAR4FFAR1DRD2 | |
| Hydrochloric Acid SCHEMBL7028247 | 0.99 | ITGB3 (0.56) | ITGB3ITGA2BFFAR4FFAR1DRD2 | |
| Hydrochloric Acid SCHEMBL6699749 | 0.99 | ITGB3 (0.56) | ITGB3ITGA2BFFAR4FFAR1DRD2 | |
| Hydrochloric Acid SCHEMBL7031484 | 0.99 | ITGB3 (0.56) | ITGB3ITGA2BFFAR4FFAR1DRD2 | |
| SCHEMBL18160779 | 0.83 | ITGB3 (0.54) | ITGB3ITGA2BFFAR4FFAR1 | |
| SCHEMBL28857157 | 0.83 | ITGB3 (0.54) | ITGB3ITGA2BFFAR4FFAR1DRD2 | |
| SCHEMBL27755780 | 0.83 | ITGB3 (0.54) | ITGB3ITGA2BFFAR4FFAR1DRD2 | |
| SCHEMBL28857113 | 0.83 | ITGB3 (0.54) | ITGB3ITGA2BFFAR4FFAR1DRD2 | |
| SCHEMBL6351624 | 0.82 | MLNR (0.39) | ITGB3ITGA2BFFAR4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286982-A2 | PROCESS FOR THE PREPARATION OF BENZOYL SUBSTITUTED BICYLIC COMPOUNDS AND CHIRAL BNEZOPYRAN DERIVATIVES | Eli Lilly & Company (US) | 2003-03-05 | — | — | EP | claimed |
| WO-2001094333-A2 | PROCESS FOR THE PREPARATION OF BENZOYL SUBSTITUTED BICYCLIC COMPOUNDS AND CHIRAL BENZOPYRAN DERIVATIVES | ELI LILLY & COMPANY (US) | 2001-12-13 | — | — | WO | claimed |
| US-6903227-B2 | Synthesis of 2-acyl substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-6855833-B2 | Methods for producing amino substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040044225-A1 | Chiral and achiral synthesis of 2-acyl substituted chromanes and their derivatives | MILLENNIUM PHARMACEUTICALS, INC. | 2004-03-04 | — | — | US | disclosed |
| US-20030233002-A1 | Synthesis of 2-Acyl substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| EP-1286982-A2 | PROCESS FOR THE PREPARATION OF BENZOYL SUBSTITUTED BICYLIC COMPOUNDS AND CHIRAL BNEZOPYRAN DERIVATIVES | Eli Lilly & Company (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001094333-A2 | PROCESS FOR THE PREPARATION OF BENZOYL SUBSTITUTED BICYCLIC COMPOUNDS AND CHIRAL BENZOPYRAN DERIVATIVES | ELI LILLY & COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001092250-A2 | SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND INTERMEDIATES THEREOF | COR THERAPEUTICS, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001092249-A2 | CHIRAL AND ACHIRAL SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND THEIR DERIVATIVES | COR THERAPEUTICS, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030233002-A1 | Synthesis of 2-Acyl substituted chromanes and intermediates thereof | PLA2G7, PAFAH1B2, PAFAH1B3 | ITGB3 1014/4885ITGA2B 678/4885FFAR4 481/4885 |
| US-20040044225-A1 | Chiral and achiral synthesis of 2-acyl substituted chromanes and their derivatives | ACAT2, ACACA, COASY | ITGB3 203/4885ITGA2B 395/4885FFAR4 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.